Stocks · News reference
Bill Ackman gifted $400 million of his Pershing Square stake to a brain research foundation after his daughter's near-fatal hemorrhage.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Pershing Square (NYSE:PS) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and
Bill Ackman said Nike's decision to add LVMH's Alexandre Arnault to its board was a 'great development' for the struggling company.
Regeneron Pharmaceuticals' stock has declined from over $1,000 to below $800 over the past two years, primarily due to challenges with its Eylea product facing biosimilar competition. However, the company shows strong fundamentals with 17% revenue growth driven by Dupixent, successful mitigation of Eylea losses through its HD formulation, and promising pipeline candidates including the weight-loss drug olatorepatide. The analyst views the stock as attractive at current levels given its long-term growth prospects and shareholder return programs.
A comprehensive market research report analyzing co-development deals in pharmaceuticals and biotechnology from 2016-2026 has been released. The report covers deal structures, financial terms, the top 25 most active dealmakers, and provides access to actual SEC-filed contract documents. Co-development partnerships are highlighted as a strategic approach for companies to share R&D costs, risks, and commercial opportunities while accelerating product development timelines.